secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunovant, Inc. (IMVT)
CIK:        0001764013
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0001764013-25-000128
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunovant Q1 net loss $120.6M; initiates two registrational trials for IMVT-1402
--------------------------------------------------------------------------------

- Cash of $598.9M provides runway through Graves' disease readout expected in 2027.
- Net loss $120.6M ($0.71/share) vs $87.2M ($0.60) in prior-year quarter.
- Initiated a second potentially registrational trial of IMVT-1402 in Graves' disease in June 2025.
- Initiated a potentially registrational trial of IMVT-1402 in Sjögren's disease in June 2025.
- Expects GD remission data from batoclimab proof-of-concept study at ATA meeting in September 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1764013/000176401325000128/0001764013-25-000128-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1764013/000176401325000128/imvt-20250811.htm
  HTML page:      https://secwatch.observer/filing/0001764013-25-000128

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer